Beyond migraine headache day reduction: Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab (P10-12.008)
Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available
10.1212/wnl.0000000000203083